QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
NASDAQ:PSTI

Pluristem Therapeutics (PSTI) Stock Forecast, Price & News

$1.42
+0.05 (+3.65%)
(As of 05/17/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.34
$1.45
50-Day Range
$1.37
$2.18
52-Week Range
$1.31
$4.55
Volume
72,182 shs
Average Volume
1.01 million shs
Market Capitalization
$45.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.99
30 days | 90 days | 365 days | Advanced Chart
Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Pluristem Therapeutics logo

About Pluristem Therapeutics

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Headlines

Pluristem: Fiscal Q3 Earnings Snapshot
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PSTI
Employees
153
Year Founded
2003

Sales & Book Value

Annual Sales
$20 thousand
Book Value
$1.80 per share

Profitability

Net Income
$-49.87 million
Pretax Margin
-20,024.79%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,054,000
Market Cap
$45.93 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
5/17/2022
Fiscal Year End
6/30/2022
Next Earnings (Estimated)
9/12/2022

Social Links


MarketRank

Overall MarketRank

1.21 out of 5 stars

Medical Sector

1185th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

184th out of 210 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -













Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

When is Pluristem Therapeutics' next earnings date?

Pluristem Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, September 12th 2022.
View our earnings forecast for Pluristem Therapeutics
.

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.05.
View Pluristem Therapeutics' earnings history
.

When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?

Pluristem Therapeutics's stock reverse split on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.

Who are Pluristem Therapeutics' key executives?
Pluristem Therapeutics' management team includes the following people:
  • Mr. Yaacov Yanay, Pres, CEO & Director (Age 51, Pay $612.6k)
  • Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 38, Pay $330.3k)
  • Mr. Lior Raviv, Chief Technology Officer
  • Ms. Efrat Livne-Hadass, VP of HR
  • Dr. Nitsan Halevy M.D., Chief Medical Officer
  • Mr. Nimrod Bar Zvi, Chief Commercial Officer
What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Protalix BioTherapeutics (PLX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

Who are Pluristem Therapeutics' major shareholders?

Pluristem Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nia Impact Advisors LLC (2.60%), Jane Street Group LLC (0.42%), Shelton Capital Management (0.40%), Green Alpha Advisors LLC (0.24%), Renaissance Technologies LLC (0.23%) and Values First Advisors Inc. (0.15%). Company insiders that own Pluristem Therapeutics stock include Clover Wolf Capital - Limited and Zami Aberman.
View institutional ownership trends for Pluristem Therapeutics
.

Which major investors are selling Pluristem Therapeutics stock?

PSTI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Shelton Capital Management, and Simplex Trading LLC.
View insider buying and selling activity for Pluristem Therapeutics
or view top insider-selling stocks.

Which major investors are buying Pluristem Therapeutics stock?

PSTI stock was bought by a variety of institutional investors in the last quarter, including Nia Impact Advisors LLC, Jane Street Group LLC, TownSquare Capital LLC, Group One Trading L.P., Green Alpha Advisors LLC, and Values First Advisors Inc.. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Clover Wolf Capital - Limited, and Zami Aberman.
View insider buying and selling activity for Pluristem Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $1.42.

How much money does Pluristem Therapeutics make?

Pluristem Therapeutics has a market capitalization of $45.93 million and generates $20 thousand in revenue each year. The biotechnology company earns $-49.87 million in net income (profit) each year or ($1.470010) on an earnings per share basis.

How many employees does Pluristem Therapeutics have?

Pluristem Therapeutics employs 153 workers across the globe.

When was Pluristem Therapeutics founded?

Pluristem Therapeutics was founded in 2003.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is www.pluristem.com.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company can be reached via phone at 972747107171, via email at [email protected], or via fax at 972-74-710-8787.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.